Cancer Patients May Be Treated With Drugs That Provide No Benefit
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
Diagnosis & Disease Information
Aggregating Data Hides Cancer Disparities Affecting Asian and NHPI Patients in the US
Aggregated data can hide disparities in cancer incidence and outcomes among Asian and Native Hawaiian/Pacific Islander patients in the US.
Immunotherapy Combo Reduces Risk of Cancer Recurrence in Early-Stage Liver Cancer
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
Cell-Free DNA Fragmentome Analysis Can Be Used to Detect Hepatocellular Carcinoma
Cell-free DNA fragmentome analysis can be used to detect hepatocellular carcinoma, according to researchers.
Radiation Dose and Inflammation Contribute to Post-SBRT Liver Dysfunction in HCC
Researchers sought to determine the relationship between direct radiation dose and inflammation and regional hepatic function after stereotactic body radiation therapy for hepatocellular carcinoma.
Most Patients With Cirrhosis Do Not Receive Hepatocellular Carcinoma Surveillance
Researchers found that hepatocellular carcinoma surveillance was underutilized among approximately 80% of patients with cirrhosis.
ERAS Program for Hepatic Resection Decreased Postoperative Complications
The effect of compliance with ERAS protocols on postoperative adverse events and length of hospital stay was evaluated in a single-center cohort study.
Sintilimab Plus IBI305 for Hepatitis B Virus-Positive Hepatocellular Carcinoma
The combination of sintilimab and IBI305 improved progression-free survival in patients with unresectable hepatocellular carcinoma.
Donafenib Bests Sorafenib in Chinese Patients With Advanced Hepatocellular Carcinoma
Overall survival was superior with donafenib.
Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma Showed Better Improvement in Patient-Reported Outcomes
Patient reported outcomes for quality of life, emotional and social functioning, and general disease symptoms were better with atezolizumab/bevacizumab compared with sorafenib monotherapy.
- Loading...
Loading...
Next post in Gastrointestinal Cancer
Loading... 
Loading...